Effectiveness and safety of using intravenous injection tranexamic acid before vaginal/caesarean delivery in order to avoid excessive blood loss after delivery.
Phase 4
- Conditions
- Health Condition 1: O720- Third-stage hemorrhage
- Registration Number
- CTRI/2024/05/067790
- Lead Sponsor
- Aradhya Garg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All women undergoing vaginal delivery/LSCS at QMH,KGMU.
2.Patient who have given written informed consent will be taken
Exclusion Criteria
1.Patient not giving written informed consent
2.Antenatal diagnosis of placenta accreta spectrum (PAS),
3.Genital tract trauma
4.Known background of thrombophilia or coagulopathy
5.Women with renal, cardiac or liver disease.
6.Known hypersensitivity with tranexamic acid.
7.Women with increased risk of arterial or venous thrombosis
8.Women with epilepsy or seizures
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method